MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/md.0000000000013437

Медицинская библиотека · Medicine · 2018

Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials.

Zhou Xinmiao, Tripathi Dhiraj, Song Tingxue, Shao Lichun, Han Bing, Zhu Jia, Han Dan, Liu Fufang, Qi Xingshun

СтатьяМетаанализСистематический обзорПеревод пока не подготовлен

Аннотация

BACKGROUND AND AIM: Acute variceal bleeding (AVB) is life-threatening. We aimed to systematically review the current evidence regarding the efficacy and safety of terlipressin for AVB in liver cirrhosis.

METHODS

We searched the PubMed, EMBASE, and Cochrane Library databases. The reference list was also hand-searched. Using a random-effect model, we combined the data obtained according to the different time points when the events developed. Odds ratio (OR) and weighted mean difference (WMD) were calculated. Quality of evidence was evaluated by the GRADE methodology.

RESULTS

Thirty randomized controlled trials with 3344 patients were included. Compared with no vasoactive drug, terlipressin significantly improved the control of bleeding within 48 hours (OR = 2.94, P = .0008) and decreased the in-hospital mortality (OR = 0.31, P = .008). Compared with somatostatin, terlipressin had a significantly higher risk of complications (OR = 2.44, P = .04). Compared with octreotide, terlipressin had a significantly inferior control of bleeding within 24 hours (OR = 0.37, P = .007). Compared with vasopressin, terlipressin had a significantly lower risk of complications (OR = 0.15, P = .02). Compared with terlipressin combined with endoscopic variceal ligation, terlipressin alone had significantly higher 5-day treatment failure (OR = 14.46, P = .01) and transfusion requirements within 49 to 120 hours (WMD = 1.20, P = .002). No outcome was significantly different between terlipressin and sclerotherapy. Compared with balloon tamponade, terlipressin significantly decreased the 30-day rebleeding (OR = 0.05, P = .001) and transfusion requirements (WMD = -2.70, P = .02). Quality of evidence was very low to moderate.

CONCLUSION

Our findings were in accordance with the current recommendations regarding terlipressin for the treatment of AVB in cirrhosis. However, due to low quality of evidence, further studies are recommended.

Для цитирования: Zhou Xinmiao, Tripathi Dhiraj, Song Tingxue, Shao Lichun, Han Bing, Zhu Jia, Han Dan, Liu Fufang, Qi Xingshun. Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials.. Medicine. 2018. DOI: 10.1097/md.0000000000013437.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.